What is Dyadic International's market cap?

Dyadic International (DYAI) has a market capitalization of $39.0M and trades on NASDAQ.

Who are Dyadic International's competitors?

Dyadic International's key competitors include Codexis, Inc., Danisco USA (DuPont), Ginkgo Bioworks Holdings, Inc., and others. These companies compete in similar markets and product categories.

Who does Dyadic International partner with?

Dyadic International's notable partners include Proliant Health and Biologicals, Fermbox Bio, Inzymes ApS, and others.

Where is Dyadic International headquartered?

Dyadic International is headquartered in United States of America and employs approximately 7 people. It has been publicly traded since 2004.

Dyadic International

DYAI

Dyadic International is a global biotechnology company that develops and commercializes precision-engineered, animal-free recombinant proteins and enzymes.

Market cap

$38.99M+29.6%

Table of contents

Earnings

Q1 2026 report

May 13, 2026

Revenue$1.1MBeat by $207.2K EPS-$0.05Miss by $0.01

Read the full report

Next report

Aug 12, 2026 (in a month)

Revenue estimate$1.0M

EPS estimate-$0.03

Competitors

By market cap

Thermo Fisher Scientific$194.99B+23.4%

International Flavors & Fragrances$20.0B+4.5%

DuPont de Nemours, Inc.$18.2B-40.4%

Revvity$12.6B+8.3%

Ginkgo Bioworks$635.6M-4.3%

DiaMedica Therapeutics$415.4M+167%

Codexis$232.7M+8.9%

Dyadic International$39.0M+41.5%

By revenue growth

Revvity+4.8%

DuPont de Nemours, Inc.+2.8%

Thermo Fisher Scientific+2.4%

International Flavors & Fragrances-5.6%

Ginkgo Bioworks-37.8%

By net margin

Thermo Fisher Scientific15.19%+0.4pp

Revvity8.26%-2.1pp

International Flavors & Fragrances7.61%+14.5pp

DuPont de Nemours, Inc.-0.419%+0.7pp

Ginkgo Bioworks-215.41%-7.7pp

Profile

Dyadic International is a global biotechnology company that develops and commercializes precision-engineered, animal-free recombinant proteins and enzymes. The company leverages its proprietary microbial expression platforms, C1 and Dapibus, to enable high-yield, low-cost production for life sciences, food and nutrition, and bio-industrial markets. Its business strategy focuses on transitioning from industrial enzyme licensing toward a commercially focused model involving direct product sales, technology licensing, and strategic manufacturing collaborations.

Competitive position

Dyadic positions itself as a disruptive platform provider offering a high-yield, scalable alternative to legacy mammalian and bacterial expression systems.

GeographiesUnited States, Netherlands, South Africa, Finland, India

Customer segmentsEnterprise, Government, Research Institutions

Business modelIP Licensing, B2B Product Sales, Contract Research and Development, Royalty-based

SuppliersCRISPR/Cas9 gene editing technology providers, Contract Research Organizations (CROs), Raw material suppliers for fermentation media

CustomersBiopharmaceutical companies, Food and beverage ingredient distributors, Industrial enzyme users, Diagnostic kit manufacturers

CountryUnited States of America

Listed2004

Employees7.0

CEOMark A. Emalfarb

SectorHealthcare

IndustryBiotechnology

Websitedyadic.com

FilingsSEC EDGAR

Questions, answered.

What is Dyadic International's market cap?: Dyadic International (DYAI) has a market capitalization of $39.0M and trades on NASDAQ.
Who are Dyadic International's competitors?: Dyadic International's key competitors include Codexis, Inc., Danisco USA (DuPont), Ginkgo Bioworks Holdings, Inc., and others. These companies compete in similar markets and product categories.
Who does Dyadic International partner with?: Dyadic International's notable partners include Proliant Health and Biologicals, Fermbox Bio, Inzymes ApS, and others.
Where is Dyadic International headquartered?: Dyadic International is headquartered in United States of America and employs approximately 7 people. It has been publicly traded since 2004.